Celon Pharma S.A. Finalised an agreement with Plexus Ventures
In line with the contractual provisions, Plexus Ventures will develop a strategy for development of drug candidates and will organise meetings with potential partners. If significant clinical progress is obtained and the parties agree on the development strategy for the drug(s), Plexus Ventures will take steps to obtain partners for the development or licensees, or entities interested in the sale of distribution rights to the Company’s innovative medicines. The selection of the strategy for the product will be associated with the market specificity and investment specificity of the drug development. Transactions in terms of licensing or sale of rights for distribution of Celon Pharma S.A. innovative drugs can take place in 2018/2019.
Maciej Wieczorek, PhD, CEO of Celon Pharma S.A. The agreement with Plexus Ventures confirms the merits of continuing further development of selected drug candidates which have the potential to be the first ones in their therapeutic class or to be characterised by significant competitive advantages. The products under development can achieve a global sales potential of more than USD 0.5 billion/year, and some of them more than USD 2 billion/year.
At the same time the Company plans balanced, independent commercialisation of its own selected specialist drugs across global markets.
A list of projects which subjects of the agreement and a roadmap for global commercialisation of Celon Pharma S.A.’s innovative portfolio.